Related references
Note: Only part of the references are listed.Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer
Takeshi Hirota et al.
CLINICAL PHARMACOKINETICS (2019)
The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance
Albina Kibirova et al.
CASE REPORTS IN ONCOLOGY (2019)
Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors
Assunta Sgambato et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
Associations between early tumor shrinkage and depth of response and clinical outcomes in patients treated with 1st-line chemotherapy for advanced gastric cancer
Hiroki Osumi et al.
GASTRIC CANCER (2018)
Selective RET kinase inhibition for patients with RET-altered cancers
V. Subbiah et al.
ANNALS OF ONCOLOGY (2018)
Toward Minimal Residual Disease-Directed Therapy in Melanoma
Florian Rambow et al.
CELL (2018)
ALK inhibitors, resistance development, clinical trials
J. M. Rothenstein et al.
CURRENT ONCOLOGY (2018)
Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation
Garry Ceccon et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
M. A. Socinski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Emergencies in the Treatment of Wandering Spleen
Osher Cohen et al.
ISRAEL MEDICAL ASSOCIATION JOURNAL (2018)
Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing
Rahul Nahar et al.
NATURE COMMUNICATIONS (2018)
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
Vivek Subbiah et al.
CANCER DISCOVERY (2018)
Landscape of osimertinib resistant mutations between the two common subtypes of EGFR 19del or L858R in NSCLC.
Yan Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion
Zofia Piotrowska et al.
CANCER DISCOVERY (2018)
Overcoming Drug Resistance by Targeting Cancer Bioenergetics with an Activatable Prodrug
Amit Sharma et al.
CHEM (2018)
Longitudinal single-cell RNA sequencing of patient-derived primary cells reveals drug-induced infidelity in stem cell hierarchy
Ankur Sharma et al.
NATURE COMMUNICATIONS (2018)
Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy
Xin Hong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience
Arjun Khunger et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2018)
Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer
Le-Le Zhang et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
Valsamo Anagnostou et al.
CANCER DISCOVERY (2017)
Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma
Xian Yang Chan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
AXL-GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases
Xiaoliang Wu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK plus NSCLC in the ALTA Trial
D. R. Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Impact of Depth of Response (DpR) on Survival in Patients with Advanced NSCLC Treated with First-Line Chemotherapy
Daniel Morgensztern et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases
Hironori Uruga et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer
Suzanne Jenkins et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2017)
EGFR T790M mutation testing within the osimertinib AURA Phase I study
Simon Dearden et al.
LUNG CANCER (2017)
JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer
Kazuhiko Shien et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Tracking the Evolution of Non-Small-Cell Lung Cancer
M. Jamal-Hanjani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin
Yong Hu et al.
ONCOTARGETS AND THERAPY (2017)
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors
Alexander Drilon et al.
CANCER DISCOVERY (2017)
MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor
Sean Caenepeel et al.
Oncotarget (2017)
Single-cell protein-mRNA correlation analysis enabled by multiplexed dual-analyte co-detection
Haibiao Gong et al.
SCIENTIFIC REPORTS (2017)
Crizotinib targets in glioblastoma stem cells
Audelaure Junca et al.
CANCER MEDICINE (2017)
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
Kiyotaka Yoh et al.
LANCET RESPIRATORY MEDICINE (2017)
Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients
Florence Koeppel et al.
PLOS ONE (2017)
Application of Liquid Biopsies in Cancer Targeted Therapy
S. Sumanasuriya et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy
C. E. McCoach et al.
ANNALS OF ONCOLOGY (2017)
BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma
Atul Kulkarni et al.
CLINICAL CANCER RESEARCH (2017)
Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer
Dennis Shin-Shian Hsu et al.
CLINICAL CANCER RESEARCH (2017)
Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer
Anna Li et al.
CLINICAL CANCER RESEARCH (2017)
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy
Sara Pilotto et al.
ANNALS OF TRANSLATIONAL MEDICINE (2017)
Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging
Jose Angel Garcia-Saenz et al.
BMC CANCER (2017)
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition
Francesco Facchinetti et al.
CANCER TREATMENT REVIEWS (2017)
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
Nicholas McGranahan et al.
CELL (2017)
EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance
Shuhang Wang et al.
CANCER LETTERS (2017)
Abstract C65: TRK kinase domain mutations that induce resistance to a pan-TRK inhibitor
Adriana Estrada-Bernal et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
Mariangela Russo et al.
CANCER DISCOVERY (2016)
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
A. Drilon et al.
ANNALS OF ONCOLOGY (2016)
Simple Method To Prepare Oligonucleotide-Conjugated Antibodies and Its Application in Multiplex Protein Detection in Single Cells
Haibiao Gong et al.
BIOCONJUGATE CHEMISTRY (2016)
Entrectinib, an oral pan-Trk, ROS1 and ALK inhibitor in TKI-naIve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results
Alexander Drilon et al.
CANCER RESEARCH (2016)
Metabolic Heterogeneity in Human Lung Tumors
Christopher T. Hensley et al.
CELL (2016)
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)
Chris Karlovich et al.
CLINICAL CANCER RESEARCH (2016)
ROS1 Kinase Inhibitors for Molecular-Targeted Therapies
M. M. Al-Sanea et al.
CURRENT MEDICINAL CHEMISTRY (2016)
The potential of liquid biopsies
Anna Buder et al.
CURRENT OPINION IN ONCOLOGY (2016)
Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts
S. Ramalingam et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases
Martin Schuler et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Glenwood Goss et al.
LANCET ONCOLOGY (2016)
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Yong Jia et al.
NATURE (2016)
A framework for understanding and targeting residual disease in oncogene-driven solid cancers
Trever G. Bivona et al.
NATURE MEDICINE (2016)
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Aaron N. Hata et al.
NATURE MEDICINE (2016)
Single-cell multimodal profiling reveals cellular epigenetic heterogeneity
Lih Feng Cheow et al.
NATURE METHODS (2016)
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05)
Akihito Tsuji et al.
TARGETED ONCOLOGY (2016)
Genomic heterogeneity of multiple synchronous lung cancer
Yu Liu et al.
NATURE COMMUNICATIONS (2016)
Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming
Praveena S. Thiagarajan et al.
ONCOTARGET (2016)
Targeted sequencing identifies genetic alterations that confer Primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)
Sun Min Lim et al.
ONCOTARGET (2016)
Spatial Heterogeneity in the Tumor Microenvironment
Yinyin Yuan
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
KRAS in Non-Small-Cell Lung Cancer: Oncogenic Addiction and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Stephane Renaud et al.
JAMA ONCOLOGY (2016)
Molecular Testing for Targeted Therapy in Advanced Non-Small Cell Lung Cancer Suitability of Endobronchial Ultrasound Transbronchial Needle Aspiration
Chiara Casadio et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2015)
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest
C. Cremolini et al.
ANNALS OF ONCOLOGY (2015)
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
Y. -L. Wu et al.
ANNALS OF ONCOLOGY (2015)
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
Matthew J. Niederst et al.
CLINICAL CANCER RESEARCH (2015)
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab
Stefania Napolitano et al.
CLINICAL CANCER RESEARCH (2015)
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Dalia Ercan et al.
CLINICAL CANCER RESEARCH (2015)
Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo
C. Gianna Hoffman-Luca et al.
CLINICAL CANCER RESEARCH (2015)
Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)
Volker Heinemann et al.
EUROPEAN JOURNAL OF CANCER (2015)
Therapeutic management of ALK+ nonsmall cell lung cancer patients
Boris Duchemann et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Stromal biology and therapy in pancreatic cancer: a changing paradigm
Albrecht Neesse et al.
GUT (2015)
Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancer
Shigehira Saji et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Melissa L. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients
Antonio Marchetti et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin
Matthew G. Oser et al.
LANCET ONCOLOGY (2015)
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
Kenneth S. Thress et al.
LUNG CANCER (2015)
Comprehensive genomic profiles of small cell lung cancer
Julie George et al.
NATURE (2015)
Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells
Devon A. Lawson et al.
NATURE (2015)
Therapy-induced tumour secretomes promote resistance and tumour progression
Anna C. Obenauf et al.
NATURE (2015)
Targeting mitochondria metabolism for cancer therapy
Samuel E. Weinberg et al.
NATURE CHEMICAL BIOLOGY (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Matthew J. Niederst et al.
NATURE COMMUNICATIONS (2015)
MET Receptor Juxtamembrane Exon 14 Alternative Spliced Variant: Novel Cancer Genomic Predictive Biomarker
Patrick C. Ma
CANCER DISCOVERY (2015)
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations
Leanne G. Ahronian et al.
CANCER DISCOVERY (2015)
NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer
Collin M. Blakely et al.
CELL REPORTS (2015)
Single-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells
Kyu-Tae Kim et al.
GENOME BIOLOGY (2015)
The Challenges and the Promise of Molecular Targeted Therapy in Malignant Gliomas
Hongxiang Wang et al.
NEOPLASIA (2015)
Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
Monika Joshi et al.
PLOS ONE (2015)
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Rakesh K. Jain
CANCER CELL (2014)
Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy
Gabriel Etienne et al.
HAEMATOLOGICA (2014)
Liquid Biopsies: Genotyping Circulating Tumor DNA
Luis A. Diaz et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
Marco Gerlinger et al.
NATURE GENETICS (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer REPLY
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells
M. K. Asiedu et al.
ONCOGENE (2014)
MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
Nikhil Wagle et al.
CANCER DISCOVERY (2014)
Complete Remission of Brain Metastases in Non-Small Cell Lung Cancer Patients Harboring an EGFR Mutation Treated with Tyrosine Kinase Inhibitor without Radiotherapy: A Report of 3 Cases
Yun Hwa Jung et al.
CASE REPORTS IN ONCOLOGY (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Deepness of response: A quantitative analysis of its impact on post-progression survival time after first-line treatment in patients with mCRC
Ulrich Robert Mansmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
Hubert Piessevaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling
Ali Bashashati et al.
JOURNAL OF PATHOLOGY (2013)
Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation
Hyeong Ryul Kim et al.
MOLECULAR ONCOLOGY (2013)
Influence of tumour micro-environment heterogeneity on therapeutic response
Melissa R. Junttila et al.
NATURE (2013)
Acquired Resistance to Crizotinib from a Mutation in CD74-ROS1
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Evolutionary dynamics of cancer in response to targeted combination therapy
Ivana Bozic et al.
ELIFE (2013)
Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer
Wei Wang et al.
CLINICAL CANCER RESEARCH (2012)
Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy
Samir E. Witta et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge et al.
LANCET ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Timothy R. Wilson et al.
NATURE (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Crizotinib for the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology
Sai-Hong Ignatius Ou et al.
ONCOLOGIST (2012)
Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
Lauren Averett Byers et al.
CANCER DISCOVERY (2012)
Ron Kinase Transphosphorylation Sustains MET Oncogene Addiction
Silvia Benvenuti et al.
CANCER RESEARCH (2011)
MET-Independent Lung Cancer Cells Evading EGFR Kinase Inhibitors Are Therapeutically Susceptible to BH3 Mimetic Agents
Weiwen Fan et al.
CANCER RESEARCH (2011)
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
Maria E. Arcila et al.
CLINICAL CANCER RESEARCH (2011)
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
R. Porta et al.
EUROPEAN RESPIRATORY JOURNAL (2011)
Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis
Elisa Benedettini et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
Alexa B. Turke et al.
CANCER CELL (2010)
Drugging Drug Resistance
Jan-Hermen Dannenberg et al.
CELL (2010)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer
Tadaaki Yamada et al.
CLINICAL CANCER RESEARCH (2010)
Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
Katharine A. Price et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
A. Singh et al.
ONCOGENE (2010)
Shifting paradigms: the seeds of oncogene addiction
Charles L. Sawyers
NATURE MEDICINE (2009)
Personalized Medicine and Inhibition of EGFR Signaling in Lung Cancer.
Adi F. Gazdar
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Co-overexpression of Met and Hepatocyte Growth Factor Promotes Systemic Metastasis in NCI-H460 Non-Small Cell Lung Carcinoma Cells
Roya Navab et al.
NEOPLASIA (2009)
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
Seiji Yano et al.
CANCER RESEARCH (2008)
Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors
Franklin L. Chen et al.
CLINICAL CANCER RESEARCH (2008)
Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer
Akiko Tatematsu et al.
CLINICAL CANCER RESEARCH (2008)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai-Hong Yun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-Mutant lung cancer reveals novel treatment strategies
Zhiwei Yu et al.
CANCER RESEARCH (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Erlotinib in lung cancer - Molecular and clinical predictors of outcome
MS Tsao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activation of hepatocyte growth factor-Met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line
S Yi et al.
NEOPLASIA (2000)
Share Paper
